Clinical features of reactive capillary hemangiomas (RCHs)
| Features | Dose cohort | All patients
(n=98) | ||
| 60 mg (n=12) | 200 mg (n=74) | 400 mg (n=12) | ||
| RCH events n (%) | 8 (66.7) | 64 (86.5) | 12 (100) | 84 (85.7) |
| Time to onset, median (range), days | 53.5 (43–114) | 18.5 (2–144) | 10 (3–32) | 19.5 (2–144) |
| No. of injections before onset, median (range) | 3.5 (3–8) | 1(1–9) | 1 (1) | 1 (1–9) |
| Peak time, median (range), days | 115 (71–169) | 84 (28–171) | 84 (70–98) | 84 (28–71) |
| No. of injections to peak time median (range) | 7 (4–12) | 5.5 (2–11) | 5 (4–6) | 5 (2–12) |
| Severity | ||||
| Grade 1 | 8 | 54 | 9 | 71 |
| Grade 2 | 0 | 10 | 3 | 13 |
| Grade 3–4 | 0 | 0 | 0 | 0 |
| Location | ||||
| Cutaneous only | 8 | 56 | 8 | 72 |
| Mucosal only | 0 | 0 | 0 | 0 |
| Mixed (cutaneous and mucosal) | 0 | 8 | 4 | 12 |